Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. - Test2 - elhamkhani - TriplyDB

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

http://www.wikidata.org/entity/Q38325814

about

Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.QSAR studies in the discovery of novel type-II diabetic therapies.Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.Main constituents of polyphenol complex from seagrasses of the genus Zostera, their antidiabetic properties and mechanisms of action.From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions.Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review.In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence.Multi-scale, whole-system models of liver metabolic adaptation to fat and sugar in non-alcoholic fatty liver disease

P2860

Q26747009-0BF2CA73-CD18-4792-9D3A-99676634ED44 Q37578702-8EF2465F-13A5-4972-B45F-9BEC92AFA5AA Q38630598-B22336AA-945E-40E2-8601-B7D6CF05AA08 Q38842531-077B7A97-17CE-47BE-AD52-293EA97AED9D Q39090639-2614F3F0-D505-4B81-BF85-2023DCA74C3C Q39200940-89AC818A-7F65-48B6-B6BB-B8B4E9D07DF0 Q39341939-002EEE8D-2C73-4F00-9F7C-95780B9B72FC Q39414496-D7530F35-ECF9-4ACB-BA1A-76B8F788BB0D Q41560616-32124BBA-B74C-49B4-816A-E75F03A05288 Q45054305-4D793F73-B5A5-4D0E-AA58-F1AF6D12DC14 Q58417407-3D882D2B-CA6B-4FE2-8809-6353F83A73B6

P2860

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

http://www.wikidata.org/entity/Q38325814

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

@en

type

label

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

@en

prefLabel

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

@en

P1433

Q38325814-87901494-E8C6-4EEC-87FB-B9CF6E61C9D0

P1476

Q38325814-1DCA37A5-C164-43FD-A4D9-74737D7291CD

P2093

Q38325814-71AB242C-E1F0-40B8-954D-B671EE4FE1D3

Q38325814-86F860EE-33E5-47E6-B8A4-BD3E67E21E3E

Q38325814-9C2633AF-66C2-4692-9202-AD7106324D88

Q38325814-E808CD64-A79E-428E-8E47-8229A72BEB6C

P2860

Q38325814-00FE1061-D187-46A0-915D-2771B81D6238

Q38325814-012186F1-5104-4E86-BDDA-DF888CE29081

Q38325814-01998093-DE90-4CE4-83B1-D9751C8C840E

Q38325814-07000984-01D5-42DB-95B9-5810C932FCA3

Q38325814-09E261D2-E1B6-453A-9930-388D4F253FC0

Q38325814-132C8549-2BE4-4AC6-8E0B-F07BF672270C

Q38325814-15BA8849-F67E-41A9-A963-1F93D44A3753

Q38325814-17D37F15-FCA1-4A4D-9606-5E769024C9B2

Q38325814-1DA78C93-5551-40EA-AF03-4F0F17C0B0FF

Q38325814-24990D74-F27B-4FD5-BF1E-90342F3EBA7D

P304

Q38325814-275414C7-167B-4E15-939C-C4D7D5A0D375

P31

Q38325814-EC88B35D-EC02-4498-9898-DDFDF11DF8BA

P356

Q38325814-394A6D9B-1EF3-4084-BDFC-CCCDE4A89BE7

P407

Q38325814-24CA8587-8994-403D-A449-E2627BCFD202

P433

Q38325814-AFDE878E-60DD-4440-911F-C8E95CAC72B2

P478

Q38325814-50E51240-4618-4FCF-AB3F-C0C42F771611

P577

Q38325814-3CAFD48B-ECC7-4476-9CF3-4114CFB2EE4C

P698

Q38325814-447EA002-4EC6-44BC-BA81-4D15F5A1BE36

P356

13543784.2015.1006359

P1433

Expert Opinion on Investigational Drugs

P1476

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

@en

P2093

Brian Tomlinson

http://www.w3.org/2001/XMLSchema#string

Miao Hu

http://www.w3.org/2001/XMLSchema#string

Paul Chan

http://www.w3.org/2001/XMLSchema#string

Zhong-Min Liu

http://www.w3.org/2001/XMLSchema#string

P2860

A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy

Withdrawal of cerivastatin from the world market

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

The organization, promoter analysis, and expression of the human PPARgamma gene

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

P304

611-621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2015.1006359

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25604802

http://www.w3.org/2001/XMLSchema#string